Navigation Links
Takeda and Resolve Therapeutics Enter Autoimmune Partnership
Date:2/27/2013

OSAKA, Japan and SEATTLE, Feb. 27, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and Resolve Therapeutics, LLC ("Resolve") today jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases.  The lead compound, RSLV-132, a novel nuclease*1 Fc fusion protein*2, will begin clinical development later this year. 

(Logo: http://photos.prnewswire.com/prnh/20130227/SF68101LOGO-a)

(Logo: http://photos.prnewswire.com/prnh/20130227/SF68101LOGO-b)

Additional Resolve clinical candidates are in the pre-clinical proof-of-concept stage.  These compounds target the degradation and elimination of autoantibody-containing immune complexes, which are thought to be the most proximal pathophysiological trigger of lupus.

Resolve will conduct all development work under the collaboration until completion of the first RSLV-132 Phase 1b/2a trial*3 in lupus patients.  Takeda has the exclusive option to license the lead compound and all other compounds from the Resolve platform upon the completion of the Phase 1b/2a trial.  Upon exercise of its option, Takeda would assume lead responsibility for worldwide development and commercialization of the Resolve products.

Under the terms of the agreement, Takeda will help fund continued development of RSLV-132 through an initial payment of $8 million to Resolve in fiscal 2012. Upon exercise of its option, Takeda would pay Resolve an option exercise fee, plus the potential for additional development milestones totaling $247 million.  Furthermore Resolve is eligible t
'/>"/>

SOURCE Resolve Therapeutics, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
2. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
3. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
4. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
5. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
6. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
7. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
8. Solta Medical And BTL Industries Resolve Patent Dispute
9. Frost & Sullivan Recognizes KAERs Game-Changing Innovating Aerosol Drug Delivery Methods for High-Dose Respiratory Disease Therapeutics
10. United Therapeutics Corporation Reports 2012 Fourth Quarter and Annual Financial Results
11. iBio And Caliber Biotherapeutics Establish License And Collaboration Relationship
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt ... interaktive PDF, verfügbar unter pharmaserialisation.com , zeigt ... sie jeweils in Kraft treten. Für ... nicht länger um das "ob", sondern darum, "wann" ...
(Date:9/19/2014)... VIENNA , Sept. 19, 2014 ... positive interim clinical data for its lead candidate ITCA ... diabetes patients with high baseline HbA1c levels at the ... for the Study of Diabetes (EASD). Data from the ... reduced levels of blood sugar in patients with poorly ...
(Date:9/19/2014)... Mass. , Sept. 19, 2014   Personal ... advanced cancer genome analysis and testing services, and ... and developing highly selective kinase inhibitors for genomically ... study of malignant mixed Mullerian tumors (MMMT), an ... system, also known as carcinosarcoma. The new ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... 2011 Seal Shield LLC today announced ... for the iPad.  The product has been designed specifically ... use in hospital settings. The Seal Shield ... which is resistant to liquids including blood and bleach. ...
... MALVERN, Pa., Feb. 21, 2011 Today, Siemens (NYSE: ... Overhage, MD, PhD, as Chief Medical Informatics Officer (CMIO), of ... of the In diana Health Information Exchange ... this not-for-profit organization. In his role at Siemens, Marc will ...
Cached Medicine Technology:Siemens Appoints Overhage as New Chief Medical Informatics Officer 2
(Date:9/19/2014)... of human cancers have abnormally upregulated chemical signals ... are controlled during tumor formation is not fully ... Fayngerts, PhD, both researchers in the department of ... of Medicine, University of Pennsylvania, and colleagues report ... cancer by targeting these pathways. , Lipid second ...
(Date:9/19/2014)... NJ (PRWEB) September 19, 2014 ... not-for-profit provider of home health care, hospice and palliative ... Bank to ring the Opening Bell yesterday at the ... a New Jersey philanthropist and social entrepreneur to care ... VNA Health Group has always worked to meet the ...
(Date:9/19/2014)... (HealthDay News) -- U.S. military troops deployed to sunny ... according to a new study. Many returning ... In some cases, military personnel developed blisters on their ... or size of their moles since being deployed overseas. ... for skin cancer, the study authors noted. "The ...
(Date:9/19/2014)... 2014 (HealthDay News) -- Although there is mounting ... most middle-aged and older adults in the United ... according to new research. Less than one-quarter ... set by the Department of Health and Human ... essential for promoting health and fitness and staying ...
(Date:9/19/2014)... The Alliance for Bangladesh Worker ... National Fire Protection Association (NFPA), a recognized international ... in a Memorandum of Understanding signed by both ... other stakeholders with information, guidance and access to ... and safety of workers in ready-made garment (RMG) ...
Breaking Medicine News(10 mins):Health News:New cancer drug target involving lipid chemical messengers 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3
... June 22 With the outbreak of H1N1 influenza in ... vaccine, which can effectively prevent the disease from spreading. The ... become a hot topic around the world. In fact, the ... industry in China and globally for quite some time now. ...
... Families by Killing 99.9% of Illness-Causing Bacteria on Soft Surfaces , ... be the only ones getting comfy and cozy on the sofa. ... home can harbor thousands of bacteria. In fact, if fabric ... on them for months.(1) , , Families now have ...
... has found that Caucasians are much more likely than people ... soft tissue cancer called Ewing,s sarcoma. In addition, among Caucasians ... women. Published in the August 1, 2009 issue of ... the study indicates that examining the gender and racial differences ...
... - Donating blood today will help save lives , ... and its divisions in Manhattan, Long Island, Hudson Valley, Brooklyn / ... donate blood in advance of the July 4th holiday weekend. ... "trauma season" for most emergency rooms. According to the Centers ...
... transplant recipients to suppress their immune systems, has a paradoxical ... Emory Vaccine Center have discovered. In experiments conducted in ... memory CD8 T cells, which enable the immune system to ... second encounter. The results were published online ahead of ...
... Pick shades with UV protection, and wear them a ... News) -- Price and style -- not protection from ... considerations when buying sunglasses, a new survey has found. ... the American Optometric Association, which conducted the survey. , ...
Cached Medicine News:Health News:Frost & Sullivan Sees Opportunities in Chinese Vaccine Industry 2Health News:Frost & Sullivan Sees Opportunities in Chinese Vaccine Industry 3Health News:Harmful Bacteria May Hide on Soft Surfaces in Your Home 2Health News:Caucasians are at higher risk of developing Ewing's sarcoma than other races 2Health News:Give Life for the Fourth of July 2Health News:Give Life for the Fourth of July 3Health News:Transplant drug stimulates immune memory 2Health News:Not All Sunglasses Are Created Equal 2
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
Medicine Products: